153 related articles for article (PubMed ID: 25227799)
1. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
[TBL] [Abstract][Full Text] [Related]
2. Targeting HSP90 Gene Expression with 17-DMAG Nanoparticles in Breast Cancer Cells.
Mellatyar H; Talaei S; Nejati-Koshki K; Akbarzadeh A
Asian Pac J Cancer Prev; 2016; 17(5):2453-7. PubMed ID: 27268613
[TBL] [Abstract][Full Text] [Related]
3. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
5. Comparison of inhibitory effect of 17-DMAG nanoparticles and free 17-DMAG in HSP90 gene expression in lung cancer.
Mellatyar H; Akbarzadeh A; Rahmati M; Ghalhar MG; Etemadi A; Nejati-Koshki K; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(20):8693-8. PubMed ID: 25374192
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
7. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of β-cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line - results of real time quantitative PCR.
Ghasemali S; Nejati-Koshki K; Tafsiri E; Rahmati-Yamchi M; Akbarzadeh A; Alizadeh E; Abbasi M; Barkhordari A; Tozihi M; Kordi S; Zarghami N
Asian Pac J Cancer Prev; 2013; 14(11):6949-53. PubMed ID: 24377631
[TBL] [Abstract][Full Text] [Related]
10. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
Onyüksel H; Mohanty PS; Rubinstein I
Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
[TBL] [Abstract][Full Text] [Related]
11. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
[TBL] [Abstract][Full Text] [Related]
12. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
[TBL] [Abstract][Full Text] [Related]
14. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
15. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
Saxena V; Hussain MD
Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
[TBL] [Abstract][Full Text] [Related]
16. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.
Tsui KH; Feng TH; Hsieh WC; Chang PL; Juang HH
Acta Pharmacol Sin; 2008 Nov; 29(11):1334-41. PubMed ID: 18954528
[TBL] [Abstract][Full Text] [Related]
17. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
Saxena V; Naguib Y; Hussain MD
Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
[TBL] [Abstract][Full Text] [Related]
18. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
[TBL] [Abstract][Full Text] [Related]
19. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
Zajac M; Gomez G; Benitez J; Martínez-Delgado B
BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
[TBL] [Abstract][Full Text] [Related]
20. Effects of 17-AAG on the cell cycle and apoptosis of H446 cells and the associated mechanisms.
Zhao X; Wang J; Xiao L; Xu Q; Zhao E; Zheng X; Zheng H; Zhao S; Ding S
Mol Med Rep; 2016 Aug; 14(2):1067-74. PubMed ID: 27279418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]